// App-Quantinova.ai

3295 : Vitiligo and other clinical melanocyte-related adverse events following tebentafusp (IMCgp100) exposure in patients with uveal melanoma

Researchers

Presenter

  • Marlana Orloff

Principal Investigators

  • Joseph J. Sacco

  • Paul Nathan

  • Chris Holland

  • Chris Cohen

  • Jane Harper

  • Shaad E. Abdullah

  • Takami Sato

  • Richard D. Carvajal

Medical Centers

  • Thomas Jefferson University, Philadelphia, PA

  • University of Liverpool, Liverpool; Clatterbridge Cancer Centre, Wirral, United Kingdom

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • Immunocore LLC, Rockville, MD

  • Immunocore, Conshohocken, PA

  • Immunocore Ltd, Oxford, United Kingdom

  • Columbia University Medical Center, New York, NY

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Uveal melanoma

  • Vitiligo

Biomarkers

  • Peripheral blood mononuclear cell

  • Glycoprotein 100

  • Human leukocyte antigen A2

  • Interferon-gamma

Drug/Treatment

  • IMCgp100

  • Interferon Gamma

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02570308

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved